Clinical trial
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With…
NCT00003809 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003809 |
|---|---|
| Title | Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
| Official title | Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, cisplatin |
| Start date | Aug 6, 1999 |
| Primary completion | Sep 1, 2004 |
| First posted | Apr 14, 2004 |
| Last update posted | Jun 22, 2023 |
| Countries | Puerto Rico, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: